

International Stem Cell Corporation Commences Trading on the OTCQX Best Market

Release: 3/4/2019 7:00:00 AM

CARLSBAD, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been approved to trade on the OTCQX Best Market in the United States. International Stem Cell Corporation upgraded to the OTCQX from the OTCQB Venture Market.

"I'm glad that ISCO was able to move up to the OTCQX Best Market, which is a significant milestone for the company as it enables a broader range of US investors to participate in our growth," said Andrey Semechkin, PhD, ISCO's Co-Chairman and CEO. "We thank the OTC Markets Group for their continued support in facilitating greater transparency and accessibility for our US stakeholders."

The company will begin trading today under the ticker "ISCO" on the OTCQX. United States investors can find current financial disclosure and Real-Time Level 2 quotes for the company at www.otcm Markets.com.

OTC Markets Group Inc., located in New York, N.Y., operates the world's largest electronic interdealer quotation system for broker dealers to trade over 10,000 securities not listed on any other United States stock exchange.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:

<http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0>

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell.

Safe harbor statement

Statements pertaining to anticipated developments and growth, progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

Russell A. Kern, PhD

Phone: 760-940-6383

Email: ir@intlstemcell.com

Or

Edison Advisors

Joseph Green

Senior Vice President, Investor Relations

(646) 653-7030

jgreen@edisongroup.com

